Quick View
| Metric | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥7153.9B | ¥7252.2B | −1.4% |
| Operating Income | ¥702.5B | ¥1088.0B | −35.4% |
| Profit Before Tax | ¥669.2B | ¥1052.2B | −36.4% |
| Net Income | ¥433.6B | ¥763.8B | −43.2% |
| ROE | 5.6% | 10.2% | - |
Executive Summary
Cumulative results for Q3 reflected not only a decline in revenue but also a significant deterioration in profitability, marking a shift from an earnings growth trend to an earnings decline phase. Revenue was ¥7,153.9B (-1.4% year on year), Operating Income was ¥702.5B (-35.4%), Profit Before Tax was ¥669.2B (-36.4%), and Net Income was ¥433.6B (-43.2%). The decline in earnings, which substantially exceeded the decline in revenue, resulted from a combination of lower gross profit margins, higher SG&A expenses, and worsening profitability in the Surgical Intervention Business.
Factors Affecting Performance
【Revenue】Revenue was ¥7,153.9B, down 1.4% year on year. By segment, Gastrointestinal Endoscopy Solutions generated ¥4,872.3B (-1.3%), while Surgical Intervention generated ¥2,280.1B (-1.5%), with both core businesses recording modest revenue declines.
【Profitability】Gross profit was ¥4,613.3B, and the gross profit margin was 64.5%, down 3.2pt from 67.7% in the same period last year. SG&A expenses increased even amid declining revenue, reaching ¥3,677.4B (+1.3%), while the SG&A ratio rose 1.4pt to 51.4%. As a result, Operating Income was ¥702.5B (-35.4%), and the Operating Income margin was 9.8% (15.0% in the same period last year). By segment, Operating Income from Gastrointestinal Endoscopy Solutions declined to ¥951.4B (-18.5%, margin of 19.5%), while Surgical Intervention fell into an Operating Loss of ¥106.0B (compared with income of ¥72.7B in the same period last year). Equity-method investment income/loss also shifted from income of ¥2.4B last year to a loss of ¥37.0B, further weighing on Profit Before Tax and Net Income. The scale of the earnings decline was large relative to the revenue decline, resulting in a decline in both revenue and earnings.
Segment Analysis
Gastrointestinal Endoscopy Solutions recorded Revenue of ¥4,872.3B (-1.3%), Operating Income of ¥951.4B (-18.5%), and a margin of 19.5% (23.6% in the same period last year). Although it remains the core contributor to consolidated earnings, its profitability has been trending downward. Surgical Intervention recorded Revenue of ¥2,280.1B (-1.5%) and an Operating Loss of ¥106.0B, a deterioration of ¥178.7B from income of ¥72.7B in the same period last year, resulting in a negative margin of 4.6%. Corporate and Other/Adjustments recorded an Operating Loss of ¥142.9B and continued to weigh on consolidated earnings even including the ¥59.95B licensing consideration from Evident Corporation. The profitability gap between the two segments is a major factor driving consolidated performance.
Key Financial Metrics
【Profitability】The Operating Income margin of 9.8% declined 5.2pt from 15.0% in the same period last year, while the Net Income margin was 6.1%, down 4.5pt from 10.5%. The gross profit margin also declined to 64.5% from 67.7%, confirming deteriorating profitability on both the cost and SG&A fronts.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥593.4B, 1.37 times Net Income of ¥433.6B, indicating that earnings continued to be supported by cash generation. However, increases in working capital, including a ¥187.6B increase in inventories, constrained OCF.【Investment Efficiency】ROE was 5.6%, and the Equity Ratio was 53.0%. Basic EPS was ¥38.87, down 41.5% from ¥66.43 in the same period last year.【Financial Soundness】Total assets were ¥14,579.2B, net assets were ¥7,733.5B, and the Equity Ratio was 53.0%, indicating a stable capital structure. Cash and cash equivalents were ¥1,694.6B, down from ¥2,525.3B in the same period last year, reflecting cash outflows for share repurchases and dividend payments.
Cash Flow Analysis
Operating Cash Flow was ¥593.4B, down 53.0% year on year. In addition to the decline in Profit Before Tax, corporate income tax payments of ¥564.2B, an increase in inventories of ¥187.6B, and a ¥30.2B decrease in trade payables constrained cash generation. Investing Cash Flow was an outflow of ¥677.1B, mainly due to ¥444.0B in acquisitions of property, plant and equipment, resulting in Free Cash Flow of negative ¥83.8B and indicating that investment could not be funded solely through operating activities. Financing Cash Flow was an outflow of ¥823.3B, including dividend payments of ¥225.6B, share repurchases of ¥500.0B, and repayments of long-term borrowings of ¥70.0B. The company also raised funds in part through ¥298.7B in bond issuances and ¥70.0B in borrowings. Consequently, cash and cash equivalents declined by ¥830.7B from ¥2,525.3B at the end of the previous fiscal year to ¥1,694.6B. The current fiscal year was therefore characterized by a reduction in cash balances while partially funding investment and shareholder returns through borrowings and bond issuance.
Quality of Earnings
Operating Cash Flow of ¥593.4B exceeded Net Income of ¥433.6B, indicating that earnings were supported by cash generation from an accrual perspective. However, equity-method investment income/loss, which is recorded outside operating activities, shifted from income of ¥2.4B in the same period last year to a loss of ¥37.0B. In addition, financial expenses of ¥87.8B exceeded financial income of ¥54.5B, resulting in net financial expenses of ¥33.4B. These factors warrant attention when evaluating recurring earnings power. Impairment losses were ¥36.5B, up from ¥24.9B in the same period last year, highlighting the issue of asset profitability in Surgical Intervention. Comprehensive income was ¥924.2B, substantially exceeding Net Income of ¥433.6B, but most of the difference consisted of foreign currency translation adjustments for foreign operations of ¥482.9B. This does not represent the underlying earnings power of the business, but rather an increase in capital items resulting from foreign exchange fluctuations.
Earnings Forecast and Guidance
The Full-Year Revenue forecast is ¥9,980.0B (+0.1% year on year), and cumulative progress for the current quarter is 71.7%, slightly below the standard progress rate of approximately 75%. Revenue of ¥2,826.1B is required in Q4, and the Full-Year earnings forecast was revised during the current quarter. Going forward, sales trends in the remaining quarter and improvement in the profitability of Surgical Intervention will be key to achieving the plan.
Shareholder Returns
The Full-Year dividend forecast is ¥30 per share, and no revision has been made to the dividend forecast. Cumulative dividend payments for the current quarter were ¥225.6B, representing a Payout Ratio of approximately 52.0% relative to Net Income of ¥433.6B. In addition, the company conducted share repurchases of ¥500.0B, resulting in a Total Return Ratio of approximately 167.3% when dividends and share repurchases are combined. As Free Cash Flow was negative ¥83.8B, shareholder returns during the current fiscal year were not fully supported by operating activities alone and instead relied on cash balances and external financing. The Equity Ratio of 53.0% is one factor supporting the continuation of shareholder returns in the near term.
Risk Factors
-
Deterioration in the profitability of the Surgical Intervention Business: Against Revenue of ¥2,280.1B (-1.5%), the business recorded an Operating Loss of ¥106.0B, a deterioration of ¥178.7B from income of ¥72.7B in the same period last year. This is the primary factor depressing the consolidated Operating Income margin, and delays in improvement could continue to affect consolidated earnings.
-
Declining profitability in the core business: Gastrointestinal Endoscopy Solutions recorded Operating Income of ¥951.4B (-18.5%) and a margin of 19.5% (23.6% in the same period last year), indicating that the profitability of this core earnings pillar is also declining. If cost increases and changes in the sales mix continue, the impact on consolidated performance could be significant.
-
Weak cash conversion and rising working capital: Operating Cash Flow was limited to ¥593.4B, down 53.0% year on year, as increases in working capital, including a ¥187.6B increase in inventories, constrained cash generation. Free Cash Flow was negative ¥83.8B. If the company remains unable to fund investment and shareholder returns solely through internal funds, its dependence on external financing may increase.
Industry Benchmark (Reference; Company Analysis)
Industry Benchmark (manufacturing)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 9.8% | 8.6% (4.3%–12.7%) | +1.2pt |
| Net Income Margin | 6.1% | 6.4% (2.8%–10.3%) | −0.4pt |
The Operating Income margin exceeds the industry median, while the Net Income margin is slightly below the median, suggesting the impact of non-operating and equity-method investment income/loss.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (year on year) | −1.4% | 3.3% (-2.1%–8.9%) | −4.7pt |
The Revenue growth rate is substantially below the industry median, with the company recording a revenue decline while peer companies secured revenue growth.
*Source: Company analysis
Key Takeaways from the Earnings Results
-
A key feature of these earnings results is that Operating Income declined 35.4% and Net Income declined 43.2%, substantially exceeding the 1.4% decline in Revenue. The deterioration in profitability on both the gross profit margin and SG&A ratio fronts was the cause, making trends in margins more important than top-line performance.
-
While Gastrointestinal Endoscopy Solutions maintained an Operating Income margin of 19.5% and remained the core contributor to consolidated earnings, Surgical Intervention fell into an Operating Loss, widening the profitability gap between the businesses. It is useful to analyze the earnings trends of the two businesses separately.
-
Operating Cash Flow exceeded Net Income, confirming cash support for earnings, but Free Cash Flow was negative ¥83.8B due to factors including the increase in inventories. The Total Return Ratio, combining dividends and share repurchases, reached approximately 167.3%, making the balance between shareholder returns and cash generation a key point identifiable from the earnings data.
This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by the company based on publicly available earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional advisor as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
Olympus delivered a weak FY2026 Q3 cumulative earnings outcome, with broadly flat sales but a material deterioration in profitability. Revenue declined 1.4% year on year to ¥715.4bn. Operating income fell 35.4% to ¥70.3bn, reducing the operating margin by 518bp to 9.8%. Net income declined 43.2% to ¥43.4bn and the net margin compressed by 447bp to 6.1%. Gross profit fell 6.0% to ¥461.3bn despite only a 1.4% revenue decline, as gross margin contracted 322bp to 64.5%. SG&A increased 1.3% to ¥367.7bn while revenue declined, lifting the SG&A-to-sales ratio by roughly 135bp to 51.4%. The revenue decline was modest across both core operating segments, but the Surgical Intervention business moved into an operating loss and was the principal earnings drag. Gastrointestinal Endoscopy Solutions remained profitable, but its segment margin fell sharply. Reported operating income also absorbed ¥28.4bn of other expenses, including ¥3.6bn of impairment losses, partly offset by ¥8.7bn of other income. Finance costs increased 39.5% to ¥8.8bn, exceeding finance income of ¥5.4bn and further reducing pre-tax earnings. The effective tax rate rose to 35.2% from 27.4%, amplifying the net-income decline relative to the operating-income decline. Operating cash flow of ¥59.3bn exceeded net income by 1.37x, which supports accrual-based earnings quality. However, operating cash flow declined 53.0% year on year, mainly reflecting ¥56.4bn of tax payments, inventory investment, and lower pre-tax profit. Free cash flow was negative ¥8.4bn after ¥44.4bn of capital expenditure. The balance sheet remains adequately capitalized, with a 53.0% equity ratio and reported debt-to-equity ratio of 0.89x. Nonetheless, cash and equivalents declined ¥83.1bn from the fiscal-year opening balance to ¥169.5bn after investment, dividends, and ¥50.0bn of share repurchases. Full-year revenue guidance of ¥998.0bn implies a 71.7% nine-month progress rate, 3.3 percentage points below the standard 75% pace, although the shortfall is not large. The revised forecast warrants attention because the group needs a stronger final quarter while restoring margin performance, particularly in Surgical Intervention.
Profitability Analysis
The reported annualized ROE is 7.5%, below the 8% caution threshold, and is explained by a 6.1% net profit margin, 0.654x annualized asset turnover, and 1.89x financial leverage. The principal negative driver is margin compression rather than leverage: operating margin declined to 9.8% from 15.0% in the prior-year period, while financial leverage remains moderate. Gross margin declined 322bp to 64.5%, indicating weaker product/mix economics and/or higher cost absorption. SG&A rose 1.3% despite a 1.4% decline in sales, creating negative operating leverage and reducing operating income by ¥38.5bn. Gastrointestinal Endoscopy Solutions is the core business by operating-income contribution, generating ¥95.1bn of operating income on ¥487.2bn of revenue. Its revenue decreased 1.3% year on year, while segment operating income fell 18.5%; segment margin compressed 412bp to 19.5% from 23.6%. Surgical Intervention revenue declined 1.5% to ¥228.0bn, but operating performance deteriorated from a ¥7.3bn profit to a ¥10.6bn loss. The Surgical Intervention margin therefore contracted 779bp to negative 4.6%, from positive 3.1%, representing the largest operational change in the portfolio. Segment-level depreciation and amortization increased 3.0% to ¥50.7bn, while revenue declined, adding to fixed-cost pressure. Other expenses rose 18.3% to ¥28.4bn, including ¥3.6bn of impairment losses, while other income increased to ¥8.7bn. The resulting operating-profit decline is not solely a one-off issue because underlying gross-margin pressure and SG&A deleverage are also evident. The tax burden factor was 0.648, reflecting a 35.2% effective tax rate and reducing conversion of pre-tax profit to net income. The interest burden of 0.953 remains sound, although the rise in finance costs should be monitored.
Growth Assessment
Revenue performance was soft but comparatively resilient, with group sales down 1.4% year on year. Gastrointestinal Endoscopy Solutions declined 1.3%, and Surgical Intervention declined 1.5%, showing that the sales slowdown was broad-based rather than isolated to one segment. The more material concern is the divergence between modest revenue contraction and the 35.4% decline in operating income. The company is pursuing a more focused medical-business portfolio and reorganized reporting segments from FY2026 Q1 to align operations around Gastrointestinal Endoscopy Solutions and Surgical Intervention. This structure makes the Surgical Intervention loss the central issue for profit recovery. The core Gastrointestinal Endoscopy Solutions franchise still produces a 19.5% segment operating margin, demonstrating meaningful underlying earnings capacity despite the year-on-year reduction. However, the 412bp margin decline in that core segment indicates that a recovery cannot rely solely on a turnaround in Surgical Intervention. The ¥6.0bn license-related consideration associated with Evident is included in segment reconciliation, providing partial support to consolidated profitability. Full-year revenue guidance of ¥998.0bn requires ¥282.6bn in Q4 revenue, versus an average ¥238.5bn per quarter during the first nine months. This implies a sequentially stronger Q4 revenue requirement, although it is consistent with a 0.1% full-year revenue growth assumption. The forecast revision signals that management has updated its operating assumptions during the year. Sustainable earnings growth will depend on gross-margin normalization, discipline over SG&A, and conversion of Surgical Intervention from loss-making to profitable growth.
Financial Health
Liquidity is sound. Current assets of ¥652.7bn exceed current liabilities of ¥400.7bn, implying a current ratio of 1.63x and positive working capital of approximately ¥251.9bn. This is above the 1.5x healthy benchmark and does not indicate a near-term current-liability coverage concern. Cash and equivalents of ¥169.5bn provide additional liquidity, although they declined by ¥83.1bn from the fiscal-year opening balance. Total equity increased to ¥773.3bn from ¥751.7bn at FY2025 end, supported by ¥92.4bn of comprehensive income, including ¥49.1bn of other comprehensive income. The equity ratio improved to 53.0% from 52.4%. Reported debt-to-equity is 0.89x, below the 2.0x aggressive-financing warning level. Borrowings and bonds were refinanced toward longer maturities: current borrowings and bonds declined ¥16.8bn to ¥78.2bn, while non-current borrowings and bonds increased ¥25.5bn to ¥159.6bn. This maturity profile shift reduces short-term refinancing pressure. Total liabilities were broadly stable at ¥684.6bn. Goodwill was ¥190.9bn, equal to 24.7% of equity and 1.58x EBITDA, both within healthy M&A-risk benchmarks. Intangible assets represented 7.1% of total assets, indicating that the capital base is not excessively dependent on acquired intangibles. Deferred tax assets increased to ¥74.6bn and should remain supported by expectations of future taxable earnings.
Notable B/S Changes
Cash and equivalents: -¥830.7bn from FY2025 end to ¥169.5bn - reflects negative free cash flow, investment spending, ¥22.6bn of dividends, and ¥50.0bn of share repurchases; liquidity remains adequate but the cash buffer has reduced. Inventories: +¥278.2bn (+14.9%) to ¥215.0bn - inventory accumulation is consistent with the 232-day inventory-days alert and increases obsolescence, demand-forecasting, and cash-conversion risk. Property, plant and equipment: +¥220.2bn (+8.4%) to ¥285.4bn - indicates continued tangible investment and capacity/operational infrastructure spending. Intangible assets: +¥101.5bn (+10.8%) to ¥104.1bn - increased investment in intangible assets adds to capital commitments, although intangibles remain a moderate 7.1% of total assets. Goodwill: +¥103.3bn (+5.7%) to ¥190.9bn - goodwill remains manageable at 24.7% of equity and 1.58x EBITDA, but should be monitored against the Surgical Intervention earnings decline. Non-current bonds and borrowings: +¥255.2bn (+19.0%) to ¥159.6bn, while current bonds and borrowings declined ¥168.0bn to ¥78.2bn - indicates a shift toward longer-term funding and reduced short-term maturity pressure.
Cash Flow Quality
Operating cash flow was ¥59.3bn, equivalent to 1.37x net income of ¥43.4bn, so reported profit remains cash-backed on an OCF-to-net-income basis. The accruals ratio of negative 1.1% is also favorable and does not suggest aggressive accrual recognition. Nevertheless, operating cash flow fell from ¥126.3bn in the prior-year period to ¥59.3bn. Income taxes paid were ¥56.4bn, compared with a ¥6.3bn inflow in the prior-year period, and were the largest identifiable cause of the operating-cash-flow decline. Working-capital movements were also unfavorable overall: inventories increased by ¥18.8bn and payables declined by ¥3.0bn, partly offset by a ¥15.2bn reduction in receivables. The cash conversion ratio of 0.49x, measured as OCF divided by EBITDA, is below the 0.7x warning threshold. This low cash conversion indicates that EBITDA is not translating efficiently into operating cash during the period, despite OCF exceeding net income. The quality alert for receivable days of 75 days indicates collection intensity above the 60-day warning level. The inventory-days alert of 232 days is substantially above both the 90-day general warning threshold and the 60-day manufacturing efficiency benchmark. The 246-day annualized cash conversion cycle is also materially above the 120-day warning threshold. These three alerts point to significant working-capital intensity, with inventory being the most material component given the ¥215.0bn balance and ¥18.8bn cash outflow. Capital expenditures rose 43.7% year on year to ¥44.4bn, and intangible-asset purchases rose to ¥19.8bn. Free cash flow was negative ¥8.4bn after capital expenditure, versus positive operating cash flow before investment. CapEx-to-depreciation was 0.88x, below 1.0x, indicating that current tangible investment is below depreciation but not at the sub-0.7x underinvestment warning level. Investment cash outflows, dividends, and repurchases together reduced cash balances, increasing the importance of restoring operating-cash conversion.
Dividend Sustainability
The full-year dividend forecast is ¥30.0 per share. Based on cumulative FY2026 Q3 basic EPS of ¥38.87 and an annualized EPS of approximately ¥51.83, the indicated annualized dividend payout ratio is approximately 58%, within the 60% sustainability benchmark. Cumulative cash dividends paid were ¥22.6bn, equal to approximately 52.0% of nine-month net income. Dividend payments were therefore covered by reported earnings during the nine-month period. However, free cash flow was negative ¥8.4bn, meaning dividends were not covered by free cash flow after capital expenditure in the reported period. Share repurchases totaled ¥50.0bn, exceeding net income on a standalone basis. Dividends plus buybacks totaled ¥72.6bn, implying a cumulative total return ratio of approximately 167% of net income. Accordingly, the dividend itself appears manageable on annualized earnings, but total shareholder distributions are being funded alongside negative free cash flow and a declining cash balance. Future distribution capacity will depend on operating-margin recovery, inventory normalization, and improvement in cash conversion.
Risk Assessment
Business risks include Surgical Intervention recorded a ¥10.6bn operating loss, versus a ¥7.3bn profit in the prior-year period, with margin declining 779bp to negative 4.6%. The magnitude of the reversal makes execution in this business the highest operational risk., Gastrointestinal Endoscopy Solutions revenue declined 1.3% and its operating margin fell 412bp to 19.5%. As the core profit contributor, continued margin pressure here would have a significant group-level effect., Inventory days of 232 days are materially above the 90-day warning threshold. This creates elevated risks of excess stock, obsolescence, weak demand forecasting, and future inventory write-downs in a medical-device portfolio., Receivable days of 75 days exceed the 60-day warning level. Longer collection periods increase working-capital needs and may constrain cash generation if customer payment behavior deteriorates., The 246-day annualized cash conversion cycle is well above the 120-day warning threshold. The combination of elevated inventory and receivable days structurally lengthens the time required to convert sales into cash..
Financial risks include Cash conversion of 0.49x is below the 0.7x quality-alert threshold. Although OCF exceeded net income, the low OCF-to-EBITDA conversion indicates that operating profitability is being absorbed by taxes and working-capital investment., Free cash flow was negative ¥8.4bn, while cash dividends and repurchases totaled ¥72.6bn. Continued negative free cash flow would require further use of cash balances or external funding for shareholder distributions., Cash and equivalents declined ¥83.1bn to ¥169.5bn during the nine-month period. The decline reflects capital expenditure, intangible investment, dividends, and buybacks, reducing the liquidity buffer., Finance costs increased to ¥8.8bn from ¥6.3bn. The current interest burden remains healthy at 0.953, but further increases in funding costs would pressure earnings conversion..
Key concerns include The main investment issue is profit sensitivity: a 1.4% revenue decline translated into a 35.4% operating-income decline because of gross-margin compression and SG&A growth above revenue growth., The effective tax rate increased to 35.2% from 27.4%, causing net income to decline faster than operating income., Impairment losses of ¥3.6bn and other expenses of ¥28.4bn reduced reported operating profit. While not the sole driver of weakness, these items add volatility to reported earnings., Goodwill represents 24.7% of equity and 1.58x EBITDA, which is currently within healthy benchmarks, but value retention remains important as profitability in Surgical Intervention has deteriorated., Medical-device demand, procedure volumes, hospital capital-spending budgets, reimbursement conditions, product quality requirements, and regulatory approvals remain industry-specific factors that can affect sales mix, pricing, and inventory management..
Investment Implications
Key takeaways include Revenue resilience was offset by sharp margin compression: operating margin fell 518bp to 9.8% and net margin fell 447bp to 6.1%., Gastrointestinal Endoscopy Solutions remains the core earnings engine with ¥95.1bn of segment operating income, but its margin deterioration requires attention., Surgical Intervention is the key turnaround variable after moving to a ¥10.6bn operating loss., The balance sheet remains relatively resilient, supported by a 53.0% equity ratio, 1.63x current ratio, and 0.89x reported debt-to-equity ratio., Cash-flow assessment is mixed: OCF exceeds net income and accrual quality is favorable, but low EBITDA cash conversion, negative free cash flow, and prolonged working-capital days are material constraints., The ¥30 per-share full-year dividend appears covered by annualized earnings, but the combination of dividend payments and ¥50.0bn in buybacks exceeded period earnings and occurred alongside negative free cash flow..
Metrics to watch include Surgical Intervention revenue growth, operating-loss reduction, and return to positive segment margin, Gastrointestinal Endoscopy Solutions segment operating margin and gross-margin recovery, Group SG&A-to-sales ratio and the extent of operating leverage, Inventory balance, inventory days, and any future impairment or write-down charges, Receivable days and annualized cash conversion cycle, OCF-to-EBITDA cash conversion and free cash flow after capital expenditure, Cash balance after shareholder distributions and refinancing activity, Q4 revenue delivery against the ¥998.0bn full-year revenue forecast.
Regarding relative positioning, Olympus retains a high-margin core gastrointestinal endoscopy franchise and a sound equity base, but current profitability and cash-conversion characteristics are weaker than those associated with leading medical-technology operators. The 9.8% operating margin remains within the broad good range but is well below the 15% excellent benchmark, while annualized ROE of 7.5% is below the 8% caution threshold. The balance sheet and moderate goodwill exposure are relative strengths; the Surgical Intervention loss and extended working-capital cycle are the principal relative weaknesses.